Bepridil
From Infogalactic: the planetary knowledge core
File:Bepridil.svg | |
Systematic (IUPAC) name | |
---|---|
N-benzyl-N-(3-isobutoxy-2-pyrrolidin-1-yl-propyl)aniline
|
|
Clinical data | |
Trade names | Vascor |
AHFS/Drugs.com | monograph |
MedlinePlus | a699051 |
Pregnancy category |
|
Routes of administration |
Oral |
Pharmacokinetic data | |
Bioavailability | Well absorbed |
Protein binding | 99% |
Metabolism | Hepatic, CYP3A4-mediated |
Biological half-life | 42 hours |
Excretion | Renal |
Identifiers | |
CAS Number | 64706-54-3 ![]() |
ATC code | C08EA02 (WHO) |
PubChem | CID: 2351 |
IUPHAR/BPS | 2337 |
DrugBank | DB01244 ![]() |
ChemSpider | 2261 ![]() |
UNII | 755BO701MA ![]() |
ChEBI | CHEBI:3061 ![]() |
ChEMBL | CHEMBL1008 ![]() |
Chemical data | |
Formula | C24H34N2O |
Molecular mass | 366.54 g/mol |
|
|
|
|
(verify) |
Bepridil (trade name Vascor) is an amine calcium channel blocker once used to treat angina. It is no longer sold in the United States.
It is nonselective.[1]
It has been discussed as a possible option in the treatment of atrial fibrillation.[2]
It has been implicated in causing ventricular arrhythmia (Torsades de pointes).
Ebola Research
In June 2015 a research paper [3] was published revealing Vascor (Bepridil) resulted in a 100% survival rate for mice exposed to Ebola during an experiment searching for potential pharmaceutical Ebola treatments; indicating its potential use in future Ebola research and therapy.[4]
References
External links
<templatestyles src="Asbox/styles.css"></templatestyles>